Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + mFOLFOX7 + binimetinib
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a **combination drug regimen** consisting of the monoclonal antibody pembrolizumab (an anti-PD-1 immunotherapy), mFOLFOX7 (a chemotherapy regimen with oxaliplatin, leucovorin, fluorouracil), and binimetinib (a MEK inhibitor). - **Pembrolizumab** is a humanized monoclonal antibody that blocks the PD-1 receptor on T cells, preventing immune evasion by tumor cells and enhancing antitumor immune response. - **mFOLFOX7** comprises oxaliplatin (a platinum agent causing DNA crosslinks), leucovorin (enhances 5-FU efficacy), and fluorouracil (an antimetabolite inhibiting thymidylate synthase, disrupting DNA synthesis). - **Binimetinib** is a small molecule inhibitor targeting MEK1/2, part of the MAPK pathway, inhibiting cell proliferation in tumors with pathway activation. This combination is under investigation for advanced or metastatic colorectal cancer, especially microsatellite stable/mismatch-repair proficient disease, and aims to improve efficacy by combining immune checkpoint inhibition, MAPK pathway suppression, and cytotoxic chemotherapy[1][3][5].
- Other names
- pembrolizumab + mFOLFOX7 + binimetinib
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)DNAMEK1 (Dual specificity mitogen-activated protein kinase kinase 1)
Beyond the preview
Go deeper on pembrolizumab + mFOLFOX7 + binimetinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + mFOLFOX7 + binimetinib.